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(57) ABSTRACT 
The present invention provides novel isolated nucleic acids 
encoding antigenic proteins derived from Sarcocystis neu 
rona, or unique fragments thereof. In particular, the inven 
tion provides novel isolated nucleic acids encoding mem 
brane-associated polypeptides SnSAG2, SnSAG3, and 
SnSAG4. Also provided are puri?ed antigenic polypeptide 
fragments encoded by the novel nucleic acid sequences set 
forth herein that encode for SnSAG2, SnSAG3, and 
SnSAG4. Also provided are isolated nucleic acids capable of 
selectively hybridizing With the nucleic acid from Sarcocys 
tis neurona. The invention also provides vectors comprising 
the nucleic acids of the invention encoding an antigenic 
protein derived from Sarcocystis neurona or a unique frag 
ment thereof and provides the vector in a host capable of 
expressing the polypeptide encoded by that nucleic acid. 
16 Claims, 5 Drawing Sheets 
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NUCLEIC ACIDS ENCODING SARCOC YST IS 
NE URONA ANTIGEN AND USES THEREOF 
The present application claims the bene?t of priority of 
US. provisional patent application No. 60/357,479 ?led 
Feb. 15, 2002. 
FIELD OF THE INVENTION 
The present Invention relates to nucleic acids of Sarco 
cyslis neurona. In particular, the present invention relates to 
nucleic acids of Sarcocyslis neurona and to nucleic acid 
reagents and antibodies for use in methods of detection and 
prevention of Sarcocyslis neurona infection. More particu 
larly, the present invention relates to novel nucleic acid 
sequences of Sarcocyslis neurona and to utiliZation thereof 
including primers, probes, antigen/antibody diagnostic kits, 
vectors for production of peptides encoding the novel 
nucleic acids, and to antigenic proteins and vaccines against 
Sarcocyslis neurona. 
BACKGROUND OF THE INVENTION 
Sarcocyslis neurona is an apicomplexan parasite that is 
the primary cause of equine protoZoal myeloencephalitis 
(EPM). Due to several factors, de?nitive pre-mortem diag 
nosis of EPM remains exceedingly difficult. In particular, the 
seroprevalence of S. neurona in horses is signi?cant, yet the 
true incidence of EPM is quite loW, thus indicating that 
infection does not equate With disease. Additionally, the 
immunoblot remains the only commercial assay available 
for testing samples from suspect EPM horses; While devel 
opment of this test Was a signi?cant advance, it is a 
decade-old, ?rst-generation assay that needs to be sup 
planted. 
EPM is a common and debilitating infectious disease that 
affects the central nervous system of horses. The ?rst 
detailed description of the disease Was published in 1970 
(Rooney et al., 1970), but it Was not until 1991 that the 
etiological agent of EPM Was isolated and designated S. 
neurona (Dubey et al., 1991). S. neurona is related to the 
human and animal pathogen Toxoplasma gondii and to the 
important veterinary pathogen Neospora spp. These species 
are phylogenetically classi?ed into the Coccidia, Which are 
all obligate intracellular parasites that produce a resistant 
oocyst during groWth in the intestinal epithelium of their 
de?nitive host. Similar to other species of Sarcocyslis, S. 
neurona has an obligatory heteroxenous life cycle, With the 
opossum (Didelphis virginiana) serving as a de?nitive host 
(Fenger et al., 1995). The intermediate host(s) include 
skunks (Cheadle et al., 2001b), raccoons (Dubey et al., 
2001c), armadillos (Cheadle et al., 2001a), and cats (Dubey 
et al., 2000), although felids may be only an experimental 
intermediate host that does not contribute to the parasite life 
cycle in nature. Horses become infected With S. neurona by 
ingesting sporocysts in feces from the opossum, but unlike 
the normal intermediate hosts, mature sarcocysts have not 
been found in equine tissues (MacKay et al., 2000); conse 
quently, the horse is currently considered an aberrant dead 
end host. The geographic range of S. neurona appears to be 
limited to the Western Hemisphere, thus EPM primarily 
affects horses in the Americas. 
Recent seroprevalence studies found that a signi?cant 
proportion (45% to 55%) of horses have antibodies against 
S. neurona (BentZ et al., 1997; Blythe et al., 1997; Saville et 
al., 1997), suggesting that these animals are commonly 
exposed to the parasite. HoWever, the incidence of EPM is 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2 
estimated to be beloW 1% (MacKay et al., 2000), indicating 
that there is a clear dichotomy betWeen simple infection With 
S. neurona and the occurrence of neurologic disease. In 
addition, early attempts at inducing disease by challenging 
horses With S. neurona sporocysts gave inconsistent results, 
and these studies Were unable to authentically reproduce 
acute EPM (Cutler et al., 2001; Fenger et al., 1997). Con 
sequently, it is apparent that other factors in addition to 
simple parasite infection are responsible for the progression 
to disease. It is Well established that a robust cell-mediated 
immune response is important for controlling infections by 
coccidian parasites (Alexander et al., 1997; BasZler et al., 
1999; Krahenbuhl and Remington, 1982), including S. neu 
rona (Dubey et al., 2001a; Marsh et al., 1997), and it is 
possible that susceptibility to EPM may be increased in 
horses With inappropriate and/or suppressed immune 
responses during S. neurona infection. Accordingly, the use 
of stress to induce a transient immunosuppression has been 
shoWn to provide some improvement to the equine challenge 
model for EPM (Saville et al., 2001). 
De?nitive antemortem diagnosis of EPM remains exceed 
ingly dif?cult, for a variety of reasons. Horses a?licted With 
EPM exhibit signs that are similar to a number of different 
neurological disorders (MacKay et al., 2000). Furthermore, 
S. neurona infection does not equate to disease, since only 
a small proportion of seropositive horses Will suffer from 
EPM; as a consequence, the detection of anti-S. neurona 
antibodies in serum provides little diagnostic information 
other than previous exposure to the parasite. Analysis of 
cerebrospinal ?uid (CSF) to reveal intrathecal antibody 
production, thus suggesting CNS infection, has improved 
the predictive value of antibody detection for EPM diagno 
sis. HoWever, interpretation of CSF antibody presence can 
be confounded by contamination of the CSF sample With 
minute amounts of serum antibodies (Miller et al., 1999), 
and it is becoming apparent that the presence of antibodies 
in the CSF is not a de?nitive indication of active disease. 
Additionally, the contemporary diagnostic assays are ham 
pered by several intrinsic problems, and they provide only 
mediocre predictive value for EPM diagnosis. Western blot 
analysis (a.k.a., immunoblot) of crude S. neurona lysate 
remains the immunodiagnostic test that is used to detect 
antibodies in suspect EPM horses (Granstrom et al., 1993). 
The continued use of the immunoblot has been necessitated 
by perceived antigenic cross-reactivity betWeen different 
species of Sarcocyslis, and the assay relies on the recogni 
tion of several antigens, primarily in the loW molecular 
Weight range, by serum/CSF antibodies (Dubey et al., 
2001b; Granstrom et al., 1993; MacKay et al., 2000). Recent 
attempts to improve the immunoblot test have included the 
use of antibodies against the related parasite Sarcocyslis 
cruzi to block cross-reactive epitopes, theoretically increas 
ing the speci?city of the immunoblot analysis for anti-S. 
neurona antibodies (Rossano et al., 2000). Unfortunately, 
Western blot analysis is primarily a research tool that is 
relatively laborious and someWhat hindered by subjectivity, 
so any improvements to the immunoblot are of limited 
value. While the immunoblot has been utiliZed for a number 
of years to help diagnose EPM, it is a ?rst-generation test 
that needs to be replaced With improved assays based on 
simpli?ed, and thus more reliable, techniques that are more 
appropriate for diagnostic use. Nucleic acid ampli?cation 
assays (polymerase chain reaction; PCR) for S. neurona 
detection have been developed based on the S. neurona 
ribosomal RNA genes (Fenger et al., 1994; Marsh et al., 
1996). These PCR-based assays detect the presence of S. 
neurona DNA, and therefore the parasite, in the horse, so 
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they can provide a de?nitive indication of active infection. 
However, prior to the present invention, these nucleic acid 
based tests have been inherently unreliable. Speci?cally, 
parasites may be very feW or non-existent in a CSF sample, 
so there Will be no target molecules (i.e., parasite genomic 
DNA) for PCR ampli?cation. More importantly, the general 
use of PCR for diagnosis is still suspect; although measures 
can be taken to improve the reliability of PCR, the technique 
continues to be troubled by both false positive and false 
negative results. 
Research efforts directed toWard understanding immunity 
against S. neurona infection and improving EPM diagnosis 
have been someWhat hampered by the lack of molecular 
information for S. neurona. The identi?cation of S. neurona 
speci?c antigens and characterization of the genes encoding 
these antigens as provided by the present invention hereby 
alloW for the production of recombinant parasite antigens 
via expression in E. coli and the subsequent generation of 
monoclonal and monospeci?c polyclonal antibodies against 
the individual S. neurona antigens. The recombinant pro 
teins and speci?c antibodies provided by the invention serve 
as valuable reagents for conducting immunological studies 
on S. neurona infections and the progression to EPM. 
Additionally, these reagents alloW for the development of 
neW and more reliable diagnostic tests; for example, a 
recombinant S. neurona antigen fumishes the key compo 
nent for a simple and ef?cient enzyme-linked immunosor 
bent assay (ELISA) that can be used to monitor speci?c 
antibodies in equine serum or CSF. As provided by the 
teachings herein, the development of an ELISA that is based 
on a single recombinant S. neurona antigen rather than 
Whole-parasite lysate provides a second-generation assay 
that signi?cantly improves current methodologies for iden 
tifying S. neurona-infected animals. Notably, the use of a 
single antigen ELISA Will alloW for a more in-depth and 
complete dissection of antibody responses to S. neurona, 
Which may distinguish betWeen horses that have been sim 
ply exposed to the parasite versus horses that are actively 
infected and suffering from EPM. 
A ?uctuating equilibrium is maintained betWeen the cell 
mediated and the humoral (antibody) responses of the ver 
tebrate immune system, and this balance Will become 
biased, depending on the immune stimulus, in an effort to 
optimize the protective response. The tWo arms of the 
immune system are characterized by Thl or Th2 lympho 
cytes that differ in their pro?le of secreted cytokines, and 
these immune factors target and regulate different effector 
cells and mechanisms. Immunoglobulin isotype sWitching is 
an important immune mechanism that alloWs the host to 
generate functional diversity in the humoral response, and 
the speci?c antibody isotype produced is largely controlled 
by the cytokines associated With the Th1 and Th2 balance 
(Finkelman et al., 1990). For example, in the mouse, a 
perturbation to the host that stimulates the immune system 
predominantly in the Th2 direction Will generate an antibody 
response that is characterized by IgE and IgGl, Whereas an 
immune response that is skeWed toWards a Th1 pro?le Will 
be characterized by IgG2a and IgG3 (Finkelman et al., 1990; 
Snapper et al., 1997). It is generally believed that a Th1 
cell-mediated response is necessary for control of coccidian 
parasites (Alexander et al., 1997; Krahenbuhl and Reming 
ton, 1982), so the role of antibody class sWitching for 
protection against S. neurona infection is unclear but may be 
secondary or unimportant. HoWever, since the antibody 
isotypes produced during an infection Will vary depending 
on the immune response that has been elicited, monitoring 
the relative levels of the speci?c isotypes Will provide a 
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means for assessing the nature of the immune response (i.e., 
Thl versus Th2) in S. neurona-infected and EPM horses. 
The selection of an antigen for development of a diagnostic 
test can be someWhat subjective since any particular patho 
gen is composed of numerous antigenic proteins. Logically, 
the target molecule in a diagnostic assay must unfailingly 
elicit a detectable antibody response in the infected animal. 
A number of previous studies have demonstrated that sur 
face antigens of the Coccidia are exceedingly immunogenic. 
In particular, the primary surface antigens of Toxoplasma 
gondii (Handman and Remington, 1980; Sharma et al., 
1983) and Neaspora caninum (HoWe et al., 1998) have been 
shoWn to be immunodominant. These surface antigens, 
designated SAGs and SAG-related sequences (SRSs), have 
been implicated in host cell attachment and invasion by the 
parasite (Dzierszinski et al., 2000; GrimWood and Smith, 
1992; Hemphill, 1996; Mineo and Kasper, 1994; Mineo et 
al., 1993), most likely through interactions With sulfated 
proteoglycans on the host cell surface (He et al., 2002; 
Jacquet et al., 2001). In addition to their probable role as 
adhesins, there is increasing evidence that some of these 
surface antigens are involved in modulation of the host 
immune response (Lekutis et al., 2001). Signi?cantly, the 
TgSAGl surface antigen of T gondii has been shoWn to 
protect mice against acute toxoplasmosis (BuloW and Boo 
throyd, 1991), and the NcSAGl (p29) major surface antigen 
of N. caninum has been used to develop an ELISA for 
detection of Neospora infection in cattle (HoWe et al., 2002). 
Collectively, these previous studies demonstrate that coc 
cidian SAGs are at least candidate proteins for the devel 
opment of both diagnostic assays and protective vaccines. 
Prior to the present invention, hoWever, it had not been 
shoWn that the surface antigens of S. neurona (i.e., SnSAG2, 
SnSAG3, and SnSAG4) are effective target molecules for 
examining immune responses in infected horses and for 
developing improved assays for EPM diagnosis. The present 
invention utilizes recombinant S. neurona SAGs that are 
provided by the invention to provide simple and reliable 
ELISAs, and these assays can be used to scrutinize speci?c 
humoral immune responses in EPM horses and for detecting 
the presence of S. neurona in a test sample. Importantly, the 
developed ELISAs are valuable as tools to aid in the 
diagnosis of EPM infection in horses. 
Nucleic acids of certain Sarcocyslis and Toxoplasma 
species are knoWn in the art. For example, Eschenbacher 
K-H et al. “Cloning and expression in Escherichia coli of 
cDNAs encoding a 3l-kilodalton surface antigen of Sarco 
cyslis muris”. Molec. Biochem. Parasitol. 1992, 53zl59il68 
(1992). Eschenbacher discloses the cloning and expression 
of a surface coat protein of Sarcocyslis muris merozoites 
consisting of 280 amino acids With a predicted size of 31 
kDa. 
Velge-Roussel F. et al. “Intranasal Immunization With 
Toxoplasma gondii SAGl induces protective cells into both 
NALT and GALT compartments. Infection and Immunity, 
2000, 68: 969*972, discloses that intra-nasal immunization 
With a SAGl protein derived from Toxoplasma gondii plus 
a cholera toxin provides protective immunity in mice. Spe 
ci?c cellular response Was achieved in nasal and mesenteric 
compartments after in. immunization. T gondii naturally 
invading the intestine of its host, in this case the mouse, and 
can be partially controlled by in. immunization With the 
protein SAGl plus CT. 
Nielsen et al. discloses the construction of a DNA vaccine 
using the recombinant form of the surface coat protein 
SAGl in Toxoplasma gondii, consisting of 824-nucleotides 
encoding the 275 amino acid protein. Animals immunized 
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With this plasmid produce anti-SAG1 antibodies Which 
recognize the native SAG1. See, Nielsen H. V et al. “Com 
plete protection against lethal Toxoplasma gondii infection 
in mice immunized With a plasmid encoding the SAG1 
gene”. Infection and Immunity, 1999, 67: 6358*6363. 
Peterson et al. discloses the use of an E. coli produced 
vaccine comprised of a recombinant Toxoplasma gondii 
SAG1 With alum as adjuvant, protecting mice against infec 
tion With T gondii. Immunization With E. coli expressing 
rSAG1 in alum induced partial protective immunity against 
lethal infection With T gondii in mice. See, Petersen E, 
Nielsen H V, Christiansen L, Spenter J. Immunization With 
E. coli produced recombinant T gondii SAG1 With alum as 
adjuvant protect mice against lethal infection with Tom 
plasma gondii. Vaccine. 1998 August;16(13):1283*9. 
Bonenfant et al. discloses intranasal immunity With SAG1 
and nontoxic mutant heat-labile enterotoxins protecting 
mice against Toxoplasma gondii. High level protection Was 
assessed by the decreased load of cerebral cysts after chal 
lenge With the 76H strain of T gondii from a group of mice 
immunized With LTR 72 plus SAG1 and LTK63 plus SAG1. 
See, Bonenfant C, Dimier-Poisson I, Velge-Roussel F, 
Buzoni-Gatel D, Del Giudice G, Rappuoli R, Bout D. 
“Intranasal immunization With SAG1 and nontoxic mutant 
heat-labile enterotoxins protects mice against Toxoplasma 
gondii”. Infect Immun. 2001 March;69(3):1605*12. 
Haumont et al. discloses that a recombinant form of 
Toxoplasma gondii SAG1 used in vaccination had a signi? 
cant protective effect against maternofetal transmission of 
tachyzoites. Absence of parasites in fetuses Was demon 
strated in 66*86% of fetuses from adult guinea pigs. There 
Was no quantitative correlation betWeen anti-SAG1 antibody 
titers and protection against maternofetal transmission. This 
is reference also demonstrates that a subunit vaccine based 
on SAG1 confers a high degree of protection against con 
genital T gondii infection. Haumont M, Delhaye L, Garcia 
L, Jurado M, Mazzu P, Daminet V, Verlant V, Bollen A, 
Beaumans R, Jacquet A. “Protective immunity against con 
genital toxoplasmosis With recombinant SAG1 protein in a 
guinea pig model”. Infect Immun. 2000 September;68(9): 
4948*53. 
Angus et al. discloses that immunization With a DNA 
plasmid encoding the SAG1 (p30) protein of Toxoplasma 
gondii is immunogenic and protective in mice. Sera of 
immunized mice shoWed recognition of T gondii tachyzoi 
tes by immuno?uorescence and exhibited high titers of 
antibody to SAG1 by ELISA. This data suggest that nucleic 
acid vaccination can provide protection against T gondii 
infection in mice. See, Angus C W, Klivington-Evans D, 
Dubey J P, Kovacs J A.” Immunization With a DNA plasmid 
encoding the SAG1 (P30) protein of Toxoplasma gondii is 
immunogenic and protective in rodents”. J Infect Dis. 2000 
January;181(1):317*24. 
Fort Dodge Animal Health, “Vaccine Development” dis 
closes that an S. neurona merozoite culture that is chemi 
cally inactivated and incorporates an adjuvant is used as an 
EPM vaccine. This vaccine has been conditionally licensed 
for use but Without any indication of its effectiveness in 
preventing Sarcocysl neurona induced EPM Fort Dodge 
Animal Health, “Vaccine Development” Discloses that an S. 
neurona merozoite culture that is chemically inactivated and 
incorporates an adjuvant is used as the EPM vaccine. Fort 
Dodge Animal Health, 20001. 
Other references of interest includezBuxton D. “Protozoan 
infections in sheep and goats: recent advances” Vet. Res. 
1998, 29 (34):289*310; O,Donoghue P J et al. “Attempted 
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immunization of sWine against acute sarcocystosis using 
cystozooite-derived vaccines”. Vet. Immunol Immuno 
pathol. 1985 January;8(1*2):83*92; BuloW R and Boo 
throyd J. C. “Protection of mice from fatal Toxoplasma 
gondii infection by immunization With p30 antigen in lipo 
somes”. J. Immunol. 1991, 147 3496*3500; Dame J B, 
MacKay R J, YoWell C A, Cutler T J, Marsh A, Greiner E C 
“S. falcalula from passerine and psittacine birds: synonymy 
With S. neurona, agent of EPM”. J. Parasitol. 1995, Decem 
ber; 81(6):930*5; Mishima M, Xuan X, Shioda A, Omata Y, 
Fujisaki K, NagasaWa H, Mikami T. “Modi?ed protection 
against Toxoplasma gondii lethal infection and brain cyst 
formation by vaccination With SAG2 and SRS1”. J Vet Med 
Sci. 2001 April;63(4):433*8; Aosai F, Mun H S, Norose K, 
Chen M, Hata H, Kobayashi M, Kiuchi M, Stauss H J, Yano 
A. “Protective immunity induced by vaccination With SAG1 
gene-transfected cells against Toxoplasma gondii infection 
in mice”. Microbiol Immunol. 1999;43(1):87*91; Artois M, 
Cliquet F, Barrat J, Schumacher C L. “Effectiveness of 
SAG1 oral vaccine for the long-term protection of red foxes 
(Vulpes vulpes) against rabies”. Vet Rec.1997, Jan. 18,140 
(3):57*9; Follmann E H, Ritter D G, Baer G M. “Evaluation 
of the safety of tWo attenuated oral rabies vaccines, SAG1 
and SAG2, in six Arctic mammals”. Vaccine. 1996 March; 
14(4):270*3; and Windeck T, Gross U.” Toxoplasma gondii 
strain-speci?c transcript levels of SAG1 and their associa 
tion With virulence”. Parasitol Res. 1996;82(8):715*9. 
Yet, despite the foregoing art, there remains a need in the 
art for a safe and effective vaccine against Sarcocyslis 
neurona. Likewise, as set forth above there is also a need in 
the art for diagnostic kits including antigen and antibody kits 
for fast and reliable diagnosis of Sarcocyslis neurona infec 
tion. 
OBJECTS OF THE INVENTION 
It is an object of the present invention to satisfy the need 
in the art by providing a novel isolated nucleic acid capable 
of encoding antigenic proteins derived from Sarcocyslis 
neurona, or unique antigenic fragments thereof. It is also an 
object of the present invention to provide puri?ed antigenic 
polypeptide fragments encoded by the novel nucleic acid 
sequences set forth herein that encode for Sarcocyslis neu 
rona. In particular, it is an object of the present invention to 
provide a puri?ed antigenic polypeptide fragment encoded 
by the nucleic acid sequences set forth herein or a selective 
portion thereof, in a pharmaceutically acceptable carrier. 
It is further an object of the present invention to provide 
isolated nucleic acids capable of selectively hybridizing With 
the nucleic acid from Sarcocyslis neurona including, but not 
limited to, primers and probes for utilization in polymerase 
chain reaction (PCR) and other nucleic acid ampli?cation 
techniques. 
Another object of the invention is to provide a vector 
comprising the nucleic acid encoding Sarcocyslis neurona or 
a unique fragment thereof and to provide the vector in a host 
capable of expressing the polypeptide encoded by that 
nucleic acid. 
One important object of the invention is to provide a 
puri?ed antibody that is selectively reactive With Sarcocyslis 
neurona or an immunodominant polypeptide provided by 
the invention or a genetic variant thereof. A particular object 
of the present invention is to provide a puri?ed monoclonal 
antibody speci?cally reactive With Sarcocyslis neurona and 
a method of detection of Sarcocyslis neurona utilizing the 
antibodies of the present invention. 
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SUMMARY OF THE INVENTION 
The present invention satis?es the need in the art by 
providing a novel isolated nucleic acid encoding an anti 
genic protein derived from Sarcocyslis neurona, or a unique 
fragment thereof. In one embodiment, the invention pro 
vides novel isolated nucleic acids encoding membrane 
associated polypeptides SnSAG2, SnSAG3, and SnSAG 4. 
The present invention also provides puri?ed antigenic 
polypeptide fragments encoded by the novel nucleic acid 
sequences set forth herein that encode for Sarcocyslis neu 
rona. In one embodiment, the invention provides puri?ed 
antigenic proteins or puri?ed antigenic polypeptide frag 
ments encoded by the novel nucleic acid sequences set forth 
herein that encode for SnSAG2, SnSAG3, and SnSAG 4. In 
another embodiment, the present invention provides a puri 
?ed antigenic polypeptide fragment encoded by the nucleic 
acid sequences set forth herein or a selective portion thereof, 
in a pharmaceutically acceptable carrier. 
The present invention also provides isolated nucleic acids 
capable of selectively hybridizing With the nucleic acid from 
Sarcocyslis neurona including, but not limited to, primers 
and probes for utiliZation in polymerase chain reaction 
(PCR) and other nucleic acid ampli?cation techniques. 
Further, the present invention provides vectors compris 
ing the isolated nucleic acids set forth herein encoding 
Sarcocyslis neurona or a unique fragment thereof and pro 
vides the vector in a host capable of expressing the polypep 
tide encoded by that nucleic acid. 
Finally, the present invention also provides a puri?ed 
polyclonal and or a monoclonal antibody speci?cally reac 
tive With Sarcocystis neurona and a method of detection of 
Sarcocyslis neurona utiliZing the antibodies of the present 
invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a sequence comparison of mature SnSAGl (SEQ 
ID NO.:31), SnSAG4 (SEQ ID NO.: 32), and SnSAG3 
(SEQ ID NO.: 33) With SmMSA (SEQ ID NO.: 34) and 
TgSAG2E (SEQ ID NO.:35). The S. neurona surface anti 
gens SnSAGl, SnSAG3 and SnSAG4 are most similar to the 
TgSAG2 family of T gondi surface antigens. The sequences 
presented in the Figure are for the mature proteins after 
cleaving off the N-terminal signal peptide and the C-termi 
nal signal for the GPI anchor. Sequence alignments of the 
predicted mature proteins revealed very moderate sequence 
identity (<25%). HoWever, the SnSAGs contain 10/12 con 
served cysteine residues that have been observed previously, 
suggesting that the SnSAGs have a tertiary structure that is 
similar to What has been determined for the TgSAGs/SRSs. 
FIG. 2 is a sequence comparison of mature SnSAG2 (SEQ 
ID NO.: 36) With TgSAGl (SEQ ID NO.: 37) and TgSRS2 
(SEQ ID NO.: 38). The sequences presented in the Figure 
are for the mature proteins after cleaving off the N-terminal 
signal peptide and the C-terminal signal for the GPI anchor. 
The S. neurona surface antigen SnSAG2 is most similar to 
the TgSAGl family of T gondii surface antigens. Similar to 
the other SnSAGs, SnSAG2 shares modest sequence iden 
tity to its TgSAG orthologues, but contains 6/6 conserved 
cysteine residues that have been observed in each half of the 
prototypical tWo-domain apicomplexan SAG. SnSAG2 Will 
also align With the carboxyl-terminal domain of the 
TgSAGs. 
FIG. 3 shoWs a Western blot analysis of the Sn SAGs in 
S. neurona meroZoites. The SnSAG genes Were expressed in 
E. coli, and monospeci?c polyclonal antisera Were generated 
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against the recombinant proteins. Western blot analysis of 
reduced antigen revealed that each SnSAG migrated signi? 
cantly higher than its predicted molecular Weight, consistent 
With What has been observed for the T gondii SAGs/SRS. 
SnSAGl and SnSAG4 co-migrated and corresponded to the 
immunodominant band at about 30*32 kDa. SnSAG2 cor 
responded to an immunodominant band at approximately 
l8*20 kDa. 
FIG. 4 shoWs the SnSAGs are membrane-associated in 
Sarcocyslis neurona meroZites. Triton X-ll4 partitioning 
assays indicated that the SnSAGs are associated With mem 
branes, consistent With their surface localiZation via gly 
colipid anchoring. Western blot analysis of the partitioned 
proteins With the SnSAG-speci?c polyclonal antisera 
revealed that all four SnSAGs Were separated exclusively 
into the detergent phase (D). The control protein, SnMIClO, 
Was partitioned into the aqueous phase (A), as expected. 
FIG. 5 shoWs that the four SnSAGs are displayed on the 
surface of Sarcocyslis neurona meroZoites. Surface biotiny 
lation of S. neurona meroZoites indicated that the four 
SnSAGs are displayed on the surface of the parasite. West 
ern blot analysis With the SnSAG-speci?c antisera revealed 
each of the SnSAGs in the biotinylated protein fraction 
precipitated With immobiliZed streptavidin. The SnSAGs 
Were not present in the non-labeled parasites, thus indicating 
that the streptavidin precipitation Were speci?c for biotin 
labeled proteins. The negative control protein (actin) Was not 
detected in the biotin-labeled/streptavidin-precipitated pro 
tein fraction. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention may be understood more readily by 
reference to the folloWing detailed description of speci?c 
embodiments and the examples included therein. As used in 
the claims, “a” can mean one or more. As can be appreciated 
by one of skill in the art, methods and materials similar or 
equivalent to those described herein can be used in the 
practice of the present invention. All publications, patent 
applications, patents, and other references mentioned herein 
are incorporated by reference in their entirety. The disclo 
sures of these publications in their entireties are hereby 
incorporated by reference into this application in order to 
more fully describe the state of the art to Which this 
invention pertains. Although the present invention has been 
described With reference to speci?c details of certain 
embodiments thereof, it is not intended that such details 
should be regarded as limitations upon the scope of the 
invention except as and to the extent that they are included 
in the accompanying claims. In the case of a con?ict With 
incorporated references, the present speci?cation, including 
de?nitions Will control. In addition, the particular embodi 
ments discussed beloW are illustrative only and not intended 
to be limiting. 
The present invention satis?es the long felt need in the art 
by providing novel isolated nucleic acid sequences Which 
encode antigenic proteins derived from Sarcocyslis neurona, 
or Which encode unique antigenic protein fragments thereof. 
As used herein, a “nucleic acid” means a chain of at least 
tWo or more nucleotides such as DNA (deoxyribonucleic 
acid) or RNA (ribonucleic acid). As used herein, a “puri?ed” 
nucleic acid is one that is substantially separated from other 
nucleic acid sequences in a cell or organism in Which the 
nucleic acid naturally occurs. Likewise, by “isolated” 
nucleic acid is meant separated from at least some of other 
nucleic acids found in the naturally-occurring organism. The 
US 7,056,733 B2 
nucleic acids of the present invention can include positive 
and negative strand RNA as Well as DNA. The above terms 
encompass double-stranded DNA, single-stranded DNA, 
and RNA and are meant to include genomic and subgenomic 
nucleic acids found in the naturally-occurring Sarcocyslis 
neurona organism. The nucleic acids contemplated by the 
present invention include a nucleic acid having sequences 
from Which a Sarcocyslis neurona cDNA can be transcribed; 
or allelic variants and/or homologs of thereof. By “capable 
of selectively hybridizing” is meant a sequence Which does 
not hybridize With other nucleic acids to prevent an adequate 
positive hybridization With nucleic acids from Sarcocyslis 
neurona and is meant to include stringent hybridization 
conditions including loW, moderate and high stringency 
conditions. Such stringency conditions are knoWn in the 
artas, e.g., in US. Patent Publication No.: 2002/0115828A1. 
By “unique fragment” is meant a fragment of the nucleic 
acids set forth in the Sequence Listing that is less than the 
full length that can selectively hybridize With a RNA, DNA 
or cDNA sequence derived from the novel sequences set 
forth herein or that can selectively hybridize With nucleic 
acids from Sarcocyslis neurona. Modi?cations to the nucleic 
acids of the invention are also contemplated as long as the 
essential structure and function of the polypeptide encoded 
by the nucleic acids is maintained. Likewise, fragments used 
as primers or probes can have substitutions so long as 
enough complementary bases exist for selective hybridiza 
tion (Kunkel et al. Methods Enzmol. 1987: 1544367, 1987). 
As one of skill in the art can appreciate, there can be 
naturally occurring allelic variants and non-naturally occur 
ring variants or modi?cations of the nucleic acids of the 
invention. For example, homologs or naturally occurring 
allelic variants of the nucleic acids of the invention having 
from about 50% and up to about 99% sequence identity are 
contemplated by the invention. Likewise, it is contemplated 
that non-naturally occurring variants or modi?cations of the 
nucleic acids of the invention can range from about 50% to 
about 99% sequence identity to native S. neurona are 
contemplated. 
In particular, one embodiment of the present invention 
provides isolated nucleic acid derived from three Sarcocyslis 
neurona cluster sequences, namely Sn Cluster 144, Sn 
Cluster 21 and Sn Cluster 4, Which comprise the nucleotide 
sequences set forth in the Sequence Listing as SEQ ID NOS: 
1, 3, and 29 respectively and the sequences complimentary 
thereto. Also provided by the invention are the correspond 
ing protein or polypeptide amino acid sequences for these 
three Sarcocyslis neurona cluster sequences. The polypep 
tide sequence comprising Sn Cluster 144 is set forth in the 
Sequence Listing as SEQ ID NO: 2. The polypeptide 
sequence comprising Sn Cluster 21 is set forth in the 
Sequence Listing as SEQ ID NO: 4 and the polypeptide 
sequence comprising Sn Cluster 4 is set forth in the 
Sequence Listing as SEQ ID NO: 30. As used herein, the 
terms “polypeptide” and “protein” are used interchangeably 
and are meant to include any peptide-linked chain of amino 
acids, regardless of length or post-translational modi?cation, 
e.g., glycosylation or phosphorylation. By “puri?ed” 
polypeptide is meant a polypeptide that has been substan 
tially separated or isolated aWay from other polypeptides in 
a cell, organism, or mixture in Which the polypeptide occurs. 
Sarcocyslis neurona is an apicomplexan parasite that can 
cause a severe neurologic disease in horses called equine 
protozoal myeloencephalitis (EPM). Similar to other mem 
bers of the Apicomplexa, S. neurona is an obligate intrac 
ellular pathogen that utilizes a number of unique structures 
and molecules (i.e., virulence factors) to support its parasitic 
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life-style. Parasite surface molecules are virulence factors 
that are typically novel and undoubtedly important since 
they are responsible for the initial interactions With the host 
cell surface and host immune response. In Toxoplasma 
gondii for example, an extensive family of 25+ surface 
antigens has been identi?ed, Which are developmentally 
regulated and exhibit various levels of sequence similarity to 
either of the major T gondii surface antigens TgSAG1 or 
TgSAG2. These surface molecules appear to be involved in 
receptor/ligand interactions With the host cell surface, and 
there is increasing evidence that some of the T gondii SAGs 
are involved in modulation of host immune responses. 
In one embodiment, the present invention provides iden 
tity and characterization of certain of the virulence factors of 
S. neurona. In particular, the present invention provides four 
isolated nucleic acids of S. neurona (genes) that encode 
parasitic surface antigens. A sequencing project Was con 
ducted that generated approximately 8500 expressed 
sequence tags (ESTs) from this organism. Examination of 
this sequence database has revealed a family of at least four 
S. neurona surface antigens that are orthologues of the 
SAG/SRS family of surface proteins in T gondii. Based on 
their homology to the T gondii SAGs, the novel S. neurona 
surface antigens have been designated SnSAGl, SnSAG2, 
SnSAG3, and SnSAG4 respectively. Each protein is pre 
dicted to contain an amino-terminal signal peptide and a 
carboxyl-terminal glycolipid anchor addition site, indicating 
surface localization, and Triton X-114 partitioning and sur 
face biotinylation assays con?rmed that all four proteins are 
membrane-associated and displayed on the S. neurona mero 
zoite surface (See, FIGS. 4 and 5). Additionally, these novel 
S. neurona proteins possess multiple conserved cysteine 
residues that have been described previously for T gondii 
SAGs and Which are likely important for the tertiary struc 
ture of the proteins (See, FIGS. 1 and 2). Due to their surface 
localization and relative homology to T gondii surface 
antigens, these S. neurona proteins have been designated 
SnSAGl, SnSAG2, SnSAG3, and SnSAG4. 
Accordingly, one embodiment of the present invention 
comprises an isolated nucleic acid as set forth in the 
Sequence listing as SEQ ID NO: 21. The nucleic acid 
identi?ed in SEQ ID NO: 21 comprises an 828-nucleotide 
open reading frame of the SnSAGl gene of Sarcocyslis 
neurona Which encodes a 276 amino acid polypeptide set 
forth in the Sequence Listing as SEQ ID NO: 22. The 
polypeptide encoded by SEQ ID NO: 22 has a predicted 
amino-terminal signal peptide (indicating expression via the 
secretory pathWay) and a glycolipid anchor addition site at 
the carboxy-terminal end (indicating surface localization). 
Database searches With the predicted protein sequence of 
SnSAGl (rSnSAGl) revealed signi?cant similarity (align 
ment score:80, E value:2><10*14) to a 31 kDa surface 
antigen from Sarcocyslis muris. 
A recombinant form of the Sarcocyslis neurona SnSAGl 
(rSnSAGl) has been expressed in E. coli. Western blot 
analysis of rSnSAG1 demonstrated that the recombinant 
antigen is recognized by antiserum from a rabbit that Was 
immunized With S. neurona merozoites and by antibodies in 
cerebrospinal ?uid (CSF) from an EPM (Sarcocyslis neu 
rona infected) horse (See, e.g., FIG. 3). 
Another embodiment of the present invention comprises 
an isolated nucleic acid as set forth in the Sequence listing 
as SEQ ID NO: 23. The nucleic acid identi?ed in SEQ ID 
NO: 23 comprises an 975 nucleotide open reading frame of 
the SnSAG2 gene of Sarcocyslis neurona Which encodes a 
168 amino acid polypeptide set forth in the Sequence Listing 
as SEQ ID NO: 24. 
US 7,056,733 B2 
11 
The present invention also provides an isolated nucleic 
acid as set forth in the Sequence listing as SEQ ID NO: 25. 
The nucleic acid identi?ed in SEQ ID NO: 25 comprises an 
1585 nucleotide open reading frame of the SnSAG3 gene of 
Sarcocyslis neurona Which encodes a 281 amino acid 
polypeptide set forth in the Sequence Listing as SEQ ID NO: 
26. 
Also provided by the present invention is an isolated 
nucleic acid as set forth in the Sequence listing as SEQ ID 
NO: 27. The nucleic acid identi?ed in SEQ ID NO: 27 
comprises an 1111 nucleotide open reading frame of the 
SnSAG4 gene of Sarcocyslis neurona Which encodes a 287 
amino acid polypeptide set forth in the Sequence Listing as 
SEQ ID NO: 28. 
As set forth more fully beloW, these genes have been 
expressed as recombinant proteins in E. coli. The recombi 
nant SnSAG proteins can be implemented into antibody 
capture ELISAs and used to detect the presence of S. 
neurona antibodies in a sample. Likewise, the recombinant 
proteins provided by the invention can be used as reagents 
for use in vaccines against S. neurona. 
Another embodiment of the present invention includes the 
discovery of additional novel expressed sequence tags (EST) 
that encode novel antigenic peptides for utiliZation in the 
vaccines and diagnostic kits as disclosed by this invention. 
In particular, in a presently preferred embodiment of the 
invention, cluster analysis of the Sarcocyslis neurona 
expressed sequence tags (ESTs) generated from the cSn.1 
cDNA library has revealed a gene family that encodes at 
least eight homologous proteins. Of the approximately 8500 
S. neurona ESTs that have been generated thus far, roughly 
540 sequences can be placed in this gene family, Which has 
been provisionally designated SnGFl (S. neurona Gene 
Family 1). Based on its relative abundance in the collection 
of S. neurona ESTs, SnGFl encodes a set of similar proteins 
(at least eight) that are highly expressed and most likely play 
signi?cant roles in the biology of S. neurona (i.e., parasite 
virulence factors). In addition to their biological importance, 
the abundance of these proteins Would suggest that they 
elicit signi?cant immune responses in infected animals. 
Collectively, the characteristics of the novel nucleic acids of 
SnGFl, and the encoded proteins therefrom, make this gene 
family Well suited for the development of improved diag 
nostics and/or vaccines for EPM as set forth herein. 
The eight SnGFl isoforms identi?ed thus far have been 
designated SnGFlaih. These genes are predicted to encode 
proteins of, e.g., 109 amino acids, 106 amino acids, and 107 
amino acids in length, and the proteins share approximately 
70% to 80% sequence identity. These proteins have a 
predicted N-terminal signal peptide and a predicted trans 
membrane domain near the C-terminus. The SnGFl mem 
bers shoW no similarity to sequences in the current public 
gene databases, suggesting that SnGFl is relatively unique 
to S. neurona. 
Accordingly, one embodiment of the present invention 
provides an isolated nucleic acid designated SnGFla Which 
comprises the nucleic acid set forth in SEQ ID NO: 5 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFla set forth in the Sequence Listing as SEQ ID NO: 
6. 
Another embodiment of the present invention provides an 
isolated nucleic acid designated SnGFlb Which comprises 
the nucleic acid set forth in SEQ ID NO: 7 and sequences 
complimentary thereto. Another embodiment of the inven 
tion comprises the polypeptide sequence encoded by 
SnGFlb set forth in the Sequence Listing as SEQ ID NO: 8. 
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Yet another embodiment of the present invention provides 
an isolated nucleic acid designated SnGFlc Which com 
prises the nucleic acid set forth in SEQ ID NO: 9 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFlc set forth in the Sequence Listing as SEQ ID NO: 
10. 
Still another embodiment of the present invention pro 
vides an isolated nucleic acid designated SnGFld Which 
comprises the nucleic acid set forth in SEQ ID NO: 11 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFld set forth in the Sequence Listing as SEQ ID NO: 
12. 
The present invention also provides an isolated nucleic 
acid designated SnGFle Which comprises the nucleic acid 
set forth in SEQ ID NO: 13 and sequences complimentary 
thereto. Another embodiment of the invention comprises the 
polypeptide sequence encoded by SnGFle set forth in the 
Sequence Listing as SEQ ID NO: 14. 
Another embodiment of the present invention provides an 
isolated nucleic acid designated SnGFlf Which comprises 
the nucleic acid set forth in SEQ ID NO: 15 and sequences 
complimentary thereto. Another embodiment of the inven 
tion comprises the polypeptide sequence encoded by 
SnGFlf set forth in the Sequence Listing as SEQ ID NO: 16. 
Yet another embodiment of the present invention provides 
an isolated nucleic acid designated SnGFl g Which com 
prises the nucleic acid set forth in SEQ ID NO: 17 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFl g set forth in the Sequence Listing as SEQ ID NO: 
18. 
Still another embodiment of the present invention pro 
vides an isolated nucleic acid designated SnGFlh Which 
comprises the nucleic acid set forth in SEQ ID NO: 19 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFlh set forth in the Sequence Listing as SEQ ID NO: 
20. 
The present invention provides isolated nucleic acids as 
set forth in the Sequence Listing and nucleic acid reagents 
derived therefrom Which can be utiliZed to diagnose and 
prevent infection of S. neurona. Puri?ed polypeptides 
encoded by the nucleic acids are also provided. These 
polypeptides can be utiliZed in methods of diagnosis or as 
vaccine components for prevention of infection. Vectors are 
also provided Which comprise the nucleic acids of the 
present invention. The vectors can be utiliZed in host expres 
sion systems to produce antigenic peptide reagents for 
diagnostic and prophylactic applications. The present inven 
tion also provides puri?ed antibodies selectively reactive 
With S. neurona. These antibodies can be used in various 
diagnostic methods or as a therapeutic. 
In one embodiment, the invention provides puri?ed anti 
genic polypeptides encoded by the nucleic acids set forth in 
the Sequence Listing. The invention also provides these 
antigenic polypeptides in a pharmaceutically acceptable 
carrier. The amino acid sequence of these polypeptides can 
be deduced from the nucleotide sequences set forth in the 
Sequence Listing. 
Puri?ed antigenic polypeptide fragments encoded by the 
nucleic acids of the present invention are also contemplated. 
As used herein, “puri?ed” means the antigen is at least 
suf?ciently free of contaminants or cell components With 
Which the antigen normally occurs to distinguish the antigen 
from the contaminants or components. Puri?ed antigenic 
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polypeptides of S. neurona and antigenic fragments thereof 
of the present invention are also referred to herein as “the 
antigen” or “the S. neurona antigen.” It is contemplated that 
the antigenic fragments can be encoded from any portion of 
the nucleic acid encoding S. neurona as set forth in the 
Sequence Listing, but especially from fragments encoded by 
the open reading frames set forth in SEQ ID NOS: 24, 26 
and 28 as described herein. Speci?cally, one example pro 
vides an approximately 12 kDa antigenic polypeptide 
encoded by an open reading frame of SEQ ID NO: 24 
consisting essentially of the amino acids encoded by the 
nucleotide as sequence set forth in the Sequence Listing as 
SEQ ID NO: 23. 
An antigenic fragment of the antigen can be isolated from 
the Whole antigen by chemical or mechanical disruption. 
The puri?ed fragments thus obtained can be tested to 
determine their antigenicity and speci?city by the methods 
taught herein. Antigenic fragments of the antigen can also be 
synthesiZed directly. An immunoreactive fragment is gen 
erally an amino acid sequence of at least about ?ve con 
secutive amino acids derived from the antigen amino acid 
sequence. 
The polypeptide fragments of the present invention can 
also be recombinant proteins obtained by cloning nucleic 
acids encoding the polypeptide in an expression system 
capable of producing the antigenic polypeptide or fragments 
thereof. 
Once the amino acid sequence of the antigen is provided, 
it is also possible to synthesiZe, using standard peptide 
synthesis techniques, peptide fragments chosen to be 
homologous to immunoreactive regions of the antigen and to 
modify these fragments by inclusion, deletion or modi?ca 
tion of particular amino acids residues in the derived 
sequences. Thus, synthesis or puri?cation of an extremely 
large number of peptides derived from the antigen is pos 
sible. 
The amino acid sequences of the present polypeptides can 
contain an immunoreactive portion of the S. neurona antigen 
attached to sequences designed to provide for some addi 
tional property, such as solubility. The amino acid sequences 
of an S. neurona antigen can include sequences in Which one 
or more amino acids have been substituted With another 
amino acid to provide for some additional property, such as 
to remove/add amino acids capable of disul?de bonding, to 
increase its bio-longevity, alter enZymatic activity, or alter 
interactions, e.g., With gastric acidity. In any case, the 
peptide should posses a bioactive property, such as immu 
noreactivity, immunogenicity, etc. 
The puri?ed polypeptide fragments thus obtained can be 
tested to determine their immunogenicity and speci?city. 
Brie?y, various concentrations of a putative immunogeni 
cally speci?c fragment are prepared and administered to an 
animal and the immunological response (e.g., the production 
of antibodies or cell mediated immunity) of an animal to 
each concentration is determined. The amounts of antigen 
administered depend on the subject, eg a horse or a guinea 
pig, the condition of the subject, the siZe of the subject, etc. 
Thereafter an animal so inoculated With the antigen can be 
exposed to the parasite to test the potential vaccine effect of 
the speci?c immunogenic fragment. The speci?city of a 
putative immunogenic fragment can be ascertained by test 
ing sera, other ?uids or lymphocytes from the inoculated 
animal for cross reactivity With other closely related Sarco 
cyslis spp. 
A vector comprising the nucleic acids of the present 
invention is also provided. The vectors of the invention can 
be in a host capable of expressing the antigenic polypeptide 
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fragments contemplated by the present invention. There are 
numerous E. coli expression vectors knoWn to one of 
ordinary skill in the art useful for the expression of the 
antigen. Other microbial hosts suitable for use include 
bacilli, such as Bacillus sublilis, and other enterobacteri 
aceae, such as Salmonella, Serralia, and various Pseudomo 
nas species. In these prokaryotic hosts one can also make 
expression vectors, Which Will typically contain expression 
control sequences compatible With the host cell (e.g., an 
origin of replication). In addition, any number of a variety of 
Well-known promoters can be present, such as the lactose 
promoter system, a tryptophan (Trp) promoter system, a 
beta-lactamase promoter system, or a promoter system from 
phage lambda. The promoters Will typically control expres 
sion, optionally With an operator sequence, and have ribo 
some binding site sequences for example, for initiating and 
completing transcription and translation. If necessary, for 
example, an amino terminal methionine can be provided by 
insertion of a Met codon 5' and in-frame With the antigen. 
Also, the carboxyterminal extension of the antigenic frag 
ments can be removed using standard oligonucleotide 
mutagenesis procedures. 
Additionally, yeast expression can be used. There are 
several advantages to yeast expression systems. First, evi 
dence exists that proteins produced in a yeast secretion 
systems exhibit correct disul?de pairing. Second, post 
translational glycosylation is ef?ciently carried out by yeast 
secretory systems. In one example, the Saccharomyces cer 
evisiae pre-pro-alpha-factor leader region (encoded by the 
MF.alpha.-l gene) is routinely used to direct protein secre 
tion from yeast (Brake et al., 1984). The leader region of 
pre-pro-alpha-factor contains a signal peptide and a pro 
segment Which includes a recognition sequence for a yeast 
protease encoded by the KEX2 gene: this enZyme cleaves 
the precursor protein on the carboxyl side of a Lys-Arg 
dipeptide cleavage-signal sequence. The antigen coding 
sequence can be fused in-frame to the pre-pro-alpha-factor 
leader region. This construct is then put under the control of 
a strong transcription promoter, such as the alcohol dehy 
drogenase I promoter or a glycolytic promoter. The antigen 
coding sequence is folloWed by a translation termination 
codon Which is folloWed by transcription termination sig 
nals. Alternatively, the antigen coding sequences can be 
fused to a second protein coding sequence, such as Sj26 or 
.beta.-galactosidase, used to facilitate puri?cation of the 
fusion protein by af?nity chromatography. The insertion of 
protease cleavage sites to separate the components of the 
fusion protein is applicable to constructs used for expression 
in yeast. 
Mammalian cells permit the expression of proteins in an 
environment that favors important post-translational modi 
?cations such as folding and cysteine pairing, addition of 
complex carbohydrate structures, and secretion of active 
protein. Vectors useful for the expression of antigen in 
mammalian cells are characterized by insertion of the anti 
gen coding sequence betWeen a strong viral promoter and a 
polyadenylation signal. The vectors can contain genes con 
ferring either gentamicin or methotrexate resistance for use 
as selectable markers. The antigen and immunoreactive 
fragment coding sequence can be introduced into a Chinese 
hamster ovary cell line using a methotrexate resistance 
encoding vector. Presence of the vector DNA in transformed 
cells can be con?rmed by Southern analysis and production 
of a cDNA or opposite strand RNA corresponding to the 
antigen coding sequence can be con?rmed by northern 
analysis. A number of other suitable host cell lines capable 
of secreting intact proteins have been developed in the art, 
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and include the CHO cell lines, HeLa cells, myeloma cell 
lines, Jurkat cells, etc. Expression vectors for these cells can 
include expression control sequences, such as an origin of 
replication, a promoter, an enhancer, and necessary infor 
mation processing sites, such as ribosome binding sites, 
RNA splice sites, polyadenylation sites, and transcriptional 
terminator sequences. Preferred expression control 
sequences are promoters derived from immunoglobulin 
genes, SV40, Adenovirus, Bovine Papilloma Virus, etc. The 
vectors containing the nucleic acid segments of interest can 
be transferred into the host cell by Well-knoWn methods, 
Which vary depending on the type of cellular host. For 
example, calcium chloride transfection is commonly utilized 
for prokaryotic cells, Whereas calcium phosphate treatment 
or electroporation may be used for other celluar hosts. 
Alternative vectors for the expression of antigen in mam 
malian cells, those similar to those developed for the expres 
sion of human gammainterferon, tissue plasminogen activa 
tor, clotting Factor VIII, hepatitis B virus surface antigen, 
protease Nexinl, and eosinophil major basic protein, can be 
employed. Further, the vector can include CMV promoter 
sequences and a polyadenylation signal available for expres 
sion of inserted nucleic acid in mammalian cells (such as 
COS7). 
The nucleic acid sequences can be expressed in hosts after 
the sequences have been operably linked to, i.e., positioned 
to ensure the functioning of, an expression control sequence. 
These expression vectors are typically replicable in the host 
organisms either as episomes or as an integral part of the 
host chromosomal DNA. Commonly, expression vectors can 
contain selection markers, e.g., tetracycline resistance or 
hygromycin resistance, to permit detection and/or selection 
of those cells transformed With the desired nucleic acid 
sequences (see, e.g., US. Pat. No. 4,704,362). 
Polynucleotides encoding a variant polypeptide may 
include sequences that facilitate transcription (expression 
sequences) and translation of the coding sequences such that 
the encoded polypeptide product is produced. Construction 
of such polynucleotides is Well knoWn in the art. For 
example, such polynucleotides can include a promoter, a 
transcription termination site (polyadenylation site in 
eukaryotic expression hosts), a ribosome binding site, and, 
optionally, an enhancer for use in eukaryotic expression 
hosts, and, optionally, sequences necessary for replication of 
a vector. 
One presently preferred vector system for expression of 
the peptides of the invention comprises the use of Alphavi 
rus vector constructs, for example, as set forth in US. Pat. 
Nos.: 5,643,576; 5,843,723; 6,156,558; and 6,242,259, the 
teachings of Which are hereby incorporated herein by ref 
erence. 
A puri?ed monoclonal antibody speci?cally reactive With 
S. neurona is also provided. The antibodies can be speci? 
cally reactive With a unique epitope of the antigen or they 
can also react With epitopes of other organisms. The term 
“reactive” means capable of binding or otherWise associat 
ing non randomly With an antigen. “Speci?cally reactive” as 
used herein refers to an antibody or other ligand that does 
not cross react substantially With any antigen other than the 
one speci?ed, in this case, S. neurona. Antibodies can be 
made as described in the Examples (see also, HarloW and 
Lane, Antibodies; A Laboratory Manual, Cold Spring Har 
bor Laboratory, Cold Spring Harbor, N.Y., 1988). Brie?y 
puri?ed antigen can be injected into an animal in an amount 
and in intervals su?icient to elicit an immune response. 
Antibodies can either be puri?ed directly, or spleen cells can 
be obtained from the animal. The cells are then fused With 
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an immortal cell line and screened for antibody secretion. 
The antibodies can be used to screen clone libraries for cells 
secreting the antigen. Those positive clones can then be 
sequenced (see, for example, Kelly et al., Bio/Technology, 
10: 1634167, (1992) and Bebbington et at., Bio/Technology, 
10: 1694175, (1992). 
The antibody can be bound to a substrate or labeled With 
a detectable moiety or both bound and labeled. The detect 
able moieties contemplated by the present invention include, 
but are not limited to ?uorescent, enzymatic and radioactive 
markers. 
A puri?ed S. neurona antigen bound to a substrate and a 
ligand speci?cally reactive With the antigen are also con 
templated. Such a puri?ed ligand speci?cally reactive With 
the antigen can be an antibody. The antibody can be a 
monoclonal antibody obtained by standard methods and as 
described herein. The monoclonal antibody can be secreted 
by a hybridoma cell line speci?cally produced for that 
purpose (HarloW and Lane, 1988). Likewise, nonhuman 
polyclonal antibodies speci?cally reactive With the antigen 
are Within the scope of the present invention. The polyclonal 
antibody can also be obtained by the standard immunization 
and puri?cation protocols (HarloW and Lane, 1988). 
The present invention provides a method of detecting the 
presence of S. neurona in a subject, comprising the steps of 
contacting an antibody-containing sample from the subject 
With a detectable mount of the antigenic polypeptide frag 
ment of the present invention and detecting the reaction of 
the fragment and the antibody, the reaction indicating the 
presence of the S. neurona or a previous infection With S. 
neurona. 
One example of the method of detecting S. neurona is 
performed by contacting a ?uid or tissue sample from the 
subject With an amount of a puri?ed antibody speci?cally 
reactive With the antigen as de?ned herein, and detecting the 
reaction of the ligand With the antigen. It is contemplated 
that the antigen Will be on intact cells containing the antigen, 
or Will be fragments of the antigen. As contemplated herein, 
the antibody includes any ligand Which binds the antigen, for 
example, an intact antibody, a fragment of an antibody or 
another reagent that has reactivity With the antigen. The ?uid 
sample of this method can comprise any body ?uid Which 
Would contain the antigen or a cell containing the antigen, 
such as blood, plasma, serum, cerebrospinal ?uid, saliva, 
feces and urine. Other possible examples of body ?uids 
include sputum, mucus, gastric juice and the like. 
Enzyme immunoassays such as immuno?uorescence 
assays (IFA), enzyme linked immunosorbent assays 
(ELISA) and immunoblotting can be readily adapted to 
accomplish the detection of the antigen. An ELISA method 
effective for the detection of the antigen can, for example, be 
as folloWs: (1) bind the antibody to a substrate; (2) contact 
the bound antibody With a ?uid or tissue sample containing 
the antigen; (3) contact the above With a secondary antibody 
bound to a detectable moiety (e.g., horseradish peroxidase 
enzyme or alkaline phosphatase enzyme); (4) contact the 
above With the substrate for the enzyme; (5) contact the 
above With a color reagent; (6) observe color change. The 
above method can be readily modi?ed to detect antibody as 
Well as antigen. 
Another immunologic technique that can be useful in the 
detection of S. neurona or previous S. neurona infection 
utilizes monoclonal antibodies (MAbs) for detection of 
antibodies speci?cally reactive With S. neurona antigen. 
Brie?y, sera or other body ?uids from the subject is reacted 
With the antigen bound to a substrate (eg an ELISA 96-Well 
plate). Excess sera is thoroughly Washed aWay. A labeled 
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(enzyme-linked, ?uorescent, radioactive, etc.) monoclonal 
antibody is then reacted With the previously reacted antigen 
serum antibody complex. The amount of inhibition of mono 
clonal antibody binding is measured relative to a control (no 
patient serum antibody). The degree of monoclonal antibody 
inhibition is a very speci?c test for a particular variety or 
strain since it is based on monoclonal antibody binding 
speci?city. MAbs can also be used for detection directly in 
cells by IFA. 
A micro-agglutination test can also be used to detect the 
presence of S. neurona in a subject. Brie?y, latex beads (or 
red blood cells) are coated With the antigen and mixed With 
a sample from the subject, such that antibodies in the tissue 
or body ?uids that are speci?cally reactive With the antigen 
crosslink With the antigen, causing agglutination. The agglu 
tinated antigen-antibody complexes form a precipitate, vis 
ible With the naked eye or capable of being detected by a 
spectrophotometer. In a modi?cation of the above test, 
antibodies speci?cally reactive With the antigen can be 
bound to the beads and antigen in the tissue or body ?uid 
thereby detected. 
In addition, as in a typical sandWich assay, the antibody 
can be bound to a substrate and reacted With the antigen 
Thereafter, a secondary labeled antibody is bound to 
epitopes not recogniZed by the ?rst antibody and the sec 
ondary antibody is detected. Since the present invention 
provides S. neurona antigen for the detection of infectious, 
S. neurona or previous S. neurona infection other serological 
methods such as ?oW cytometry and immunoprecipitation 
can also be used as detection methods. 
In the diagnostic methods taught herein, the antigen can 
be bound to a substrate and contacted by a ?uid sample such 
as serum, cerebrospinal ?uid, urine, saliva, feces or gastric 
juice. This sample can be taken directly from the patient or 
in a partially puri?ed form. In this manner, antibodies 
speci?c for the antigen (the primary antibody) Will speci? 
cally react With the bound antigen. Thereafter, a secondary 
antibody bound to, or labeled With, a detectable moiety can 
be added to enhance the detection of the primary antibody. 
Generally, the secondary antibody or other ligand Which is 
reactive, either speci?cally With a different epitope of the 
antigen or nonspeci?c ally With, the ligand or reacted 
antibody, Will be selected for its ability to react With multiple 
sites on the primary antibody. Thus, for example, several 
molecules of the secondary antibody can react With each 
primary antibody, making the primary antibody more detect 
able. 
The detectable moiety Will alloW visual detection of a 
precipitate or a color change, visual detection by micros 
copy, or automated detection by spectrometry, radiometric 
measurement or the like. Examples of detectable moieties 
include ?uorescein and rhodamine (for ?uorescence micros 
copy), horseradish peroxidase (for either light or electron 
microscopy and biochemical detection), biotin-streptavidin 
(for light or electron microscopy) and alkaline phosphatase 
(for biochemical detection by color change). The detection 
methods and moieties used can be selected, for example, 
from the list above or other suitable examples by the 
standard criteria applied to such selections (HarloW and 
Lane, 1988). 
The antigen, e.g., a puri?ed antigenic polypeptide frag 
ment encoded by the Sequence Listing of this invention can 
be used in the construction of a vaccine comprising an 
immunogenic mount of the antigen and a pharmaceutically 
acceptable carrier. The vaccine can be the entire antigen, the 
antigen on an intact S. neurona organism, E. coli or other 
strain, or an epitope speci?c to the antigen. The vaccine can 
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also be potentially cross-reactive With antibodies to other 
antigens. The vaccine can then be used in a method of 
preventing EPM or other complications of S. neurona infec 
tion. 
Immunogenic amounts of the antigen can be determined 
using standard procedures. Brie?y, various concentrations of 
a putative speci?c immunoreactive epitope are prepared, 
administered to an animal and the immunological response 
(e.g., the production of antibodies) of an animal to each 
concentration is determined. 
The pharmaceutically acceptable carrier can comprise 
saline or other suitable carriers (Amon, R. (Ed.) Synthetic 
Vaccines I: 83*92, CRC Press, Inc., Boca Raton, Fla., 1987). 
An adjuvant can also be a part of the carrier of the vaccine, 
in Which case it can be selected by standard criteria based on 
the antigen used, the mode of administration and the subject 
(Arnon, R. (Ed.), 1987). Methods of administration can be 
by oral or sublingual means, or by injection, depending on 
the particular vaccine used and the subject to Whom it is 
administered. 
It can be appreciated from the above that the vaccine can 
be used as a prophylactic or a therapeutic modality. Thus, the 
invention provides methods of preventing or treating S. 
neurona infection and the associated diseases by adminis 
tering the vaccine to a subject. 
Nucleic acid vaccines against S. neurona are also con 
templated by the invention. The antigenic agent for use in 
the vaccines of the invention can be any nucleic acid, e.g., 
as set forth in the Sequence Listing, that can stimulate an 
immune response against, e.g., SnSAG2, SnSAG3 or 
SnSAG4 When administered to a subject. Suitable nucleic 
acids include those that encode the native proteins of S. 
neurona, e.g., SnSAG2, SnSAG3 or SnSAG4 protein or a 
variant or antigenic peptide fragment thereof, such as, e.g., 
the nucleic acid set forth in the Sequence listing as SEQ ID 
NO:23, SEQ ID NO:25 or SEQ ID NO:27. The nucleic acid 
used as a vaccine can be e.g., a naked DNA, or the nucleic 
acid can be incorporated in an expression vector as set forth 
herein, e.g., in an Alpha virus vector (see, e.g., Rosenberg, 
S. A., Immunity 10:281, 1999). 
The presence of S. neurona can also be determined by 
detecting the presence of a nucleic acid speci?c for S. 
neurona or the antigens of S. neurona encoded by the nucleic 
acids set forth herein. The present invention provides a 
method of detecting the presence of S. neurona in a subject, 
comprising detecting the presence of the nucleic acid encod 
ing S. neurona. As set forth more fully in the examples 
beloW, the speci?city of these sequences for S. neurona can 
be determined by conducting a computerized comparison 
With knoWn sequences, catalogued in GenBank, a comput 
eriZed database, using the computer programs Word Search 
or FASTA of the Genetics Computer Group (Madison, Wis.), 
Which search the catalogued nucleotide sequences for simi 
larities to the nucleic acid in question. 
The nucleic acid speci?c for S. neurona can be detected 
utiliZing a nucleic acid ampli?cation technique, such as 
polymerase chain reaction or ligase chain reaction. Altema 
tively, the nucleic acid is detected utiliZing direct hybrid 
iZation or by utiliZing a restriction fragment length poly 
morphism. For example, the present invention provides a 
method of detecting the presence of S. neurona comprising 
ascertaining the presence of a nucleotide sequence associ 
ated With a restriction endonuclease cleavage site. In addi 
tion, PCR primers Which hybridize only With nucleic acids 
speci?c for S. neurona can be utiliZed. The presence of 
ampli?cation indicates the presence of S. neurona sequence. 
In another embodiment a restriction fragment of a nucleic 
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acid sample can be sequenced directly using, techniques 
known in the art and described herein and compared to the 
known unique sequence to detect S. neurona. In a further 
embodiment, the present invention provides a method of 
detecting the presence of S. neurona by selective ampli? 
cation by the methods described herein. In yet another 
embodiment S. neurona can be detected by directly hybrid 
izing the unique sequence With a S. neurona selective 
nucleic acid probe. Furthermore, the nucleotide sequence 
could be ampli?ed prior to hybridization by the methods 
described above. 
Alternative probing techniques, such as ligase chain reac 
tion (LCR), involve the use of mismatch probes, i.e., probes 
Which are fully complementary With the target except at the 
point of the mutation. The target sequence is then alloWed to 
hybridize both With oligonucleotides Which are fully 
complementary and have oligonucleotides containing a mis 
match, under conditions Which Will distinguish betWeen the 
tWo. By manipulating the reaction conditions, it is possible 
to obtain hybridization only Where there is full complemen 
tarity. If a mismatch is present there is signi?cantly reduced 
hybridization. 
The polymerase chain reaction (PCR) and reverse tran 
scriptase PCR are techniques that amplify speci?c nucleic 
acid sequences With remarkable e?iciency. Repeated cycles 
of denaturation, primer annealing and extension carried out 
With polymerase; e.g., a heat stable enzyme Taq polymerase, 
leads to exponential increases in the concentration of desired 
nucleic acid sequences. Given a knoWledge of the nucleotide 
sequence of S. neurona as set forth herein, synthetic oligo 
nucleotides can be prepared Which are complementary to 
sequences Which ?ank the nucleic acid of interest. Each 
oligonucleotide is complementary to one of the tWo strands. 
The nucleic acid can be denatured at high temperatures (e.g., 
95.degree. C.) and then reannealed in the presence of a large 
molar excess of oligonucleotides. The oligonucleotides, 
oriented With their 3' ends pointing toWards each other, 
hybridize to opposite strands of the target sequence and 
prime enzymatic extension along the nucleic acid template. 
The end product is then denatured again for another cycle. 
After this three-step cycle has been repeated several times, 
ampli?cation of a nucleic acid segment by more than one 
million-fold can be achieved. The resulting nucleic acid may 
then be directly sequenced. 
In yet another method, PCR may be folloWed by restric 
tion endonuclease digestion With subsequent analysis of the 
resultant products. Nucleotide substitutions can result in the 
gain or loss of speci?c restriction endonuclease sites. The 
gain or loss of a restriction endonuclease recognition site 
facilitates the detection of the organism using restriction 
fragment length polymorphism (RFLP) analysis or by detec 
tion of the presence or absence of a polymorphic restriction 
endonuclease site in a PCR product that spans the sequence 
of interest. 
For RFLP analysis, nucleic acid is obtained, for example 
from the blood, cerebrospinal ?uid, gastric specimen, saliva, 
dental plaque, other bodily ?uids of the subject suspected of 
containing S. neurona, is digested With a restriction endo 
nuclease, and subsequently separated on the basis of size by 
agarose gel electrophoresis. The Southern blot technique can 
then be used to detect, by hybridization With labeled probes, 
the products of endonuclease digestion. The patterns 
obtained from the Southern blot can then be compared. 
Using such an approach, S. neurona nucleic acid is detected 
and their mobility on the gel by determining the number of 
bands detected and comparing this pattern to the nucleic acid 
from S. neurona. 
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Similar creation of additional restriction sites by nucle 
otide substitutions at the disclosed mutation sites can be 
readily calculated by reference to the genetic code and a list 
of nucleotide sequences recognized by restriction endonu 
cleases. Single strand conformational analysis (SSCA) 
o?‘ers a relatively quick method of detecting sequence 
changes. Which may be appropriate in at least some 
instances. 
In general, primers for PCR and LCR are usually about 20 
bp in length and the preferable range is from l5i25 bp. 
Better ampli?cation is obtained When both primers are the 
same length and With roughly the same nucleotide compo 
sition. Denaturation of strands usually takes place at about 
94.degree. C. and extension from the primers is usually at 
about 72.degree. C. The annealing temperature varies 
according to the sequence under investigation. Examples of 
reaction times are: 20 mins denaturing; 35 cycles of 2 min, 
1 min, 1 min for annealing, extension and denaturation; and 
?nally a 5 min extension step. 
PCR ampli?cation of speci?c alleles (PASA) is a rapid 
method of detecting single-base mutations or polymor 
phisms. PASA (also knoWn as allele speci?c ampli?cation) 
involves ampli?cation With tWo oligonucleotide primers 
such that one is allele-speci?c. The desired allele is e?i 
ciently ampli?ed, While the other allele(s) is poorly ampli 
?ed because it mismatches With a base at or near the 3' end 
of the allele-speci?c primer. Thus, PASA or the related 
method of PAMSA may be used to speci?cally amplify the 
mutation sequences of the invention. Where such ampli? 
cation is done on S. neurona isolates or samples obtained 
from an individual, it can serve as a method of detecting the 
presence of S. neurona. As mentioned above, a method 
knoWn as ligase chain reaction (LCR) can be used to 
successfully detect a single-base substitution. LCR probes 
may be combined or multiplexed for simultaneously screen 
ing for multiple di?‘erent mutations. Thus, LCR can be 
particularly useful Where, as here, multiple mutations are 
predictive of the same disease. 
The present invention is more particularly described in the 
folloWing examples Which are intended as illustrative only 
since numerous modi?cations and variations therein Will be 
apparent to those skilled in the art. 
EXAMPLES 
Identi?cation and Characterization of SnSAGl 
Surface biotinylation of extracellular merozoites revealed 
only tWo dominant labeled molecules that migrate at about 
30 kDa and 16 kDa in SDS-PAGE. Analysis of a S. neurona 
EST database (currently 1800+ sequences) identi?ed an 
orthologue of the 31-kDa surface antigen from Sarcocyslis 
muris. The sequence of the S. neurona surface antigen gene, 
designated SnSAGl, is predicted to encode a 276-residue 
protein With an amino-terminal signal peptide and a car 
boxy-terminal GPI anchor addition. Antiserum raised 
against recombinant SnSAGl recognized a 25-kDa antigen 
in Western blots of non-reduced S. neurona lysates, consis 
tent With the molecular Weight predicted for the mature 
SnSAGl. Under reducing conditions, SnSAGl migrated 
aberrantly at about 30 kDa, similar to What has been 
observed in Western blot analyses of reduced T gondii 
surface antigens. Immuno?uorescence labeling of SnSAGl 
during intracellular groWth of S. neurona indicated that the 
protein is expressed throughout schizogony. Interestingly, a 
?lamentous staining pattern Was observed in intermediate 
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schizonts that likely re?ects localization of the surface 
antigen to previously-described invaginations of the sch 
izont surface membrane. 
Materials and Methods 
Parasite Culture 
S. neurona strain SN3 [Granstrom, 1992 #1600] mero 
zoites Were propagated by serial passage in bovine turbinate 
(BT) cells and maintained in RPMI 1640 medium supple 
mented With 10% fetal bovine serum, 2 mM sodium pyru 
vate, Pen/Strep Fungizone (BioWhittaker, Inc.). Extracellu 
lar merozoites Were harvested and puri?ed from disrupted 
host cell monolayers by ?ltration through 3.0 pm mem 
branes, as described previously for Neaspora caninum 
[HoWe, 1997 #1372]. 
Immunoscreen of S. neurona cDNA Library 
Construction and analyses of the cSn.1 S. neurona mero 
zoite cDNA library has been described previously [HoWe, 
2001 #1787]. The library Was plaqued for 3 hrs at 420 C. on 
XL 1-Blue MRF' E. coli host cells (Stratagene) groWn on 
150 mm NZY agar plates. When plaques became visible, 
plates Were overlayed With nitrocellulose ?lters previously 
soaked in 10 mM isopropyl-[3-D-thiogalactopyranoside 
(IPTG) for an additional 3 hr incubation at 370 C. Filters 
Were lifted from the plates, Washed With TNT buffer (10 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% TWeen 20), and 
blocked in phosphate buffered saline (PBS), 5% dry milk, 
5% normal goat serum, 0.05% TWeen 20. 
Antigenic cDNA clones Were identi?ed by screening With 
cerebrospinal ?uid (CSF) from a horse that had been natu 
rally infected With S. neurona and exhibited a high titer of 
intrathecal antibodies against S. neurona in Western blot 
analysis. Prior to screening the S. neurona cDNA library, the 
CSF Was diluted 1:20 in PBS, 0.1% dry milk, 0.1% normal 
goat serum, 0.05% TWeen 20 and incubated for 30 min With 
?lters carrying plaque lifts of a previously-described N. 
caninum cDNA library [HoWe, 1999 #1759] to remove 
antibodies that Were reactive With E. coli and phage proteins. 
After adsorption of potential cross-reactive antibodies, the 
diluted CSF solution Was incubated for 1 hr With the cSn.1 
?lters. After Washing, ?lters Were incubated for 1 hr With 
goat anti-equine IgG conjugated to horseradish peroxidase 
(HRP) (Jackson Immunoresearch Labs, Inc.) diluted to 
1:10,000. Immuno-reactive phage plaques Were picked With 
sterile pipet tips and suspended in 40 pl of SM buffer (50 
mM Tris-HCl, pH 7.5, 100 mM NaCl, 8 mM MgSO4, 0.01% 
gelatin). The cDNA inserts Were PCR ampli?ed using the T3 
and T7 oligonucleotide primers, and the resulting products 
Were analyzed by agarose gel electrophoresis. Sequencing 
reactions using T3 primer Were conducted on the ampli?ed 
cDNAs to provide a preliminary identi?cation of the immu 
noreactive clones. Phagemid excision Was performed on 
selected cDNA clones, and plasmids Were rescued in SOLR 
cells according to the manufacturer’s protocol (Stratagene). 
S. neurona EST Database Searches and Sequence Analyses 
S. neurona homologues to previously-characterized coc 
cidian surface antigens Were identi?ed in the S. neurona 
clustered EST database (See, e.g., paradb.cis.upenn.edu/ 
sarco/index.html) using the BLAST (basic local alignment 
search tool) set of programs [Altschul, 1990 #616]. At the 
time the database Was searched, it contained 686 consensus 
sequences that had been generated from 1883 S. neurona 
ESTs. Selected cDNAs Were obtained from the archived 
collection of EST clones and sequenced using ABI Prism 
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BigDye Terminator Cycle Sequencing reaction mix (Perkin 
Elmer Applied Biosystems). The reactions Were puri?ed 
using Centri-Sep spin columns (Princeton Separations), and 
the eluted extension products Were resolved and analyzed on 
an ABI 310 Genetic Analyzer. Sequence analyses Were 
conducted With Genetics Computer Group (GCG) softWare 
[Devereux, 1984 #1176] and programs available on the 
National Center for Biotechnology Information (NCBI) Web 
site (See, e.g., WWW.ncbi.nlm.nih.gov/) and the Expert Pro 
tein Analysis System (ExPASy) server of the SWiss Institute 
of Bioinformatics (See, e.g., WWW.expasy.ch/). Multiple 
sequence alignments Were performed using Multalin soft 
Ware [Corpet, 1988 #2046]. The sequence reported herein 
has been deposited into GenBank under accession number 
AY032845. 
Recombinant SnSAG1 Expression and Generation of Poly 
clonal Antiserum 
The SnSAG1 open reading frame Without the predicted 
amino-terminal signal peptide and the carboxyl-terminal 
hydrophobic tail Was ampli?ed by PCR from the pSnAg8 
cDNA using primers that introduce a NdeI restriction site 
prior to base 45 (numbered from the initiation codon) and an 
XhoI site after base 743. The ampli?cation product Was 
digested With NdeI and XhoI, ligated into NdeI/XhoI-di 
gested pET22b expression vector (Novagen), and trans 
formed into INVotF' E. coli. The resulting expression plas 
mid, designated prSnSAG1, Was transformed into BL21 
CodonPlus E. coli (Stratagene), and a clone that expressed 
high levels of recombinant SnSAG1 (rSnSAG1) Was 
selected for use. The histidine-tagged rSnSAGl Was puri?ed 
by nickel-column chromatography according to the manu 
facturer’s protocol (Novagen), and monospeci?c polyclonal 
antisera Were produced against the puri?ed protein by 
immunization of a rabbit and rat (Cocalico Biologicals, 
Inc.). 
Western Blot Analysis 
Parasites Were lysed in sodium dodecyl sulfate (SDS) 
sample buffer supplemented With protease inhibitor cocktail 
(Sigma) and 2% 2-mercaptoethanol, and the lysates Were 
separated in 10% or 12% polyacrylamide gels [Laemmli, 
1970 #393]. Proteins Were transferred to nitrocellulose 
membranes by semidry electrophoretic transfer in Tris 
glycine buffer (pH 8.3). Membranes Were blocked With PBS 
containing 5% nonfat dry milk, 5% goat serum, and 0.05% 
TWeen 20, and then incubated for 1 hr With primary anti 
body. After Washing, membranes Were incubated With HRP 
conjugated immunoglobulin G secondary antibody (Jackson 
Immunoresearch Labs, Inc.). Blots Were Washed, processed 
for chemiluminescence using Supersignal substrate (Pierce 
Chemical Company), and exposed to ?lm. 
Biotinylation of Surface Proteins and Precipitation With 
Immobilized Streptavidin 
Approximately 3><107 freshly harvested merozoites Were 
resuspended in 1 ml cold PBS (pH 7.8). Sulfo-N-hydroxy 
succinimide-biotin (Pierce) Was added to a concentration of 
0.5 mg/ml and incubated at room temperature for 30 min. 
The labeled parasites Were Washed tWice With 5 ml of PBS 
and stored at —200 C. 
The labeled parasite pellet Was lysed With 1 ml radioim 
munoprecipitation assay (RIPA) buffer (50 mM Tris [pH 
7.5], 1% Triton X-100, 0.5% sodium deoxycholate, 0.2% 
SDS, 100 mM NaCl, 5 mM EDTA) supplemented With 
RNase, DNase, protease inhibitor cocktail, and the sample 
Was centrifuged at 16,000><g to remove the insoluble frac 
tion. The soluble proteins Were incubated With UltraLink 
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immobilized streptavidin (Pierce), and the precipitated 
biotin-labeled protein fraction Was analyzed by Western 
blotting, as described above. 
Immuno?uorescent Labeling of Extracellular and Intracel 
lular Parasites 
For detection of SnSAGl on extracellular parasites and in 
trails deposited by gliding parasites, freshly lysed meroZoi 
tes Were suspended in fresh RPMI 1640 and incubated on 
poly-L-lysine-coated slides for approximately 30 min. 
Slides Were Washed With PBS, and the parasites Were ?xed 
in 2.5% formalin-PBS containing 0.01% glutaraldehyde. For 
detection of SnSAGl on intracellular parasites, meroZoites 
Were inoculated onto BT cells groWn on LabTek chamber 
slides (Nunc). At 24 hr, 48 hr, or 72 hr post-inoculation, the 
cells Were ?xed in 2.5% formalin-PBS/0.01% glutaralde 
hyde and permeabliZed With 0.2% TritonX-100. After incu 
bation With primary antibody, the slides Were rinsed, then 
incubated With ?uorescein isothiocyanate (FITC)-conju 
gated goat anti-rabbit IgG (Jackson Immunoresearch Labs, 
Inc.). The slides Were mounted in Vectashield With DAPI 
(Vector Laboratories, Inc.) and examined With a Zeiss axio 
scope equipped for epi?uorescence microscopy. 
Results 
Isolation and Analysis of Immunoreactive cDNA Clones 
A primary screen of the cSn.1 cDNA library identi?ed 
multiple immunoreactive phage plaques, and a total of 25 
plaques Were isolated and resuspended in SM buffer. Ampli 
?cation of the cDNA inserts With T3 and T7 oligonucle 
otides revealed that 22 of the phage clones had similar 
lengths of approximately 1500 base pairs (bp), and sequence 
analysis using T3 primer indicated that these 22 cDNAs 
represent the same gene. A secondary screen Was performed 
on ?ve of the selected cDNAs, and tWo highly reactive 
phage clones, designated SnAgI.8 and SnAgI.9, Were chosen 
for further analyses. 
To obtain a preliminary identi?cation of the parasite 
protein encoded by the selected cDNAs, the SnAgI.9 clone 
Was used to a?inity purify antibodies that bind the antigen 
expressed by this clone, and the eluted antibodies Were used 
to probe a Western blot of S. neurona meroZoite lysate. As 
shoWn in FIG. 1, the puri?ed antibodies reacted With an 
approximately 31-kDa antigen in reduced S. neurona lysate. 
Furthermore, the antigen revealed by the phage-puri?ed 
antibodies comigrated With a protein that is recognized by 
equine or rabbit antisera against S. neurona as the major 
immunodominant antigen of this parasite (FIG. 1, lanes 2 
and 3). This result implies that the 22 matching cDNA clones 
isolated during the library screen and represented by 
SnAgI.8 and SnAgI.9 encode the immunodominant antigen 
of S. neurona. 
Full-length sequence analysis of SnAgI.8 revealed a 
cDNA insert of 1493 nucleotides, With an open reading 
frame (ORF) that encodes a 276 amino acid protein. 
Sequence analysis of SnAgI.9 indicated that this clone Was 
virtually identical to SnAgI.8, although its 3' untranslated 
region (UTR) Was approximately 160 nucleotides longer due 
to an alternative polyadenylation site. A hydrophobicity plot 
of the encoded protein shoWed hydrophobic domains at both 
termini, Which correspond to a predicted signal peptide at 
the amino terminus and a GPI anchor addition sequence at 
the carboxyl terminus (data not shoWn). The signal peptide 
cleavage is predicted to occur at Alals-Argl6 (SignalP; 
[Nielsen, 1997 #2047], and the most likely GPI transami 
dase cleavage site is predicted to be at Ala247-Asn248 (DGPI; 
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SWiss Institute of Bioinformatics). A single N-glycosylation 
site Was predicted at residues 140*143. Removal of the 
N-terminal and C-terminal signal sequences results in a 
mature protein of 242 amino acids that has a predicted 
molecular Weight of 24.2 kDa before any potential post 
translational modi?cations (e.g., glycolipid anchor addition, 
glycosylation). 
To identify homology to previously characteriZed 
sequences, BLAST searches [Altschul, 1990 #616] of the 
non-redundant GenBank databases Were conducted With the 
SnAgI.8 coding sequence as the query. These searches 
revealed a statistically signi?cant similarity to the 31 kDa 
major surface antigen of Sarcocyslis muris [Eschenbacher, 
1992 #1767] and a less signi?cant but recogniZable simi 
larity to several SAG2-related surface antigens from T 
gondii [Lekutis, 2000 #2049]. (FIG. 2). In conjunction With 
the Western blot analysis and the predictions of a signal 
peptide and a GPI-anchor addition, these results suggested 
that the gene represented by the SnAgI.8 and SnAgI.9 
cDNAs encodes an immunodominant surface antigen of S. 
neurona; consequently, We tentatively designated this pro 
tein SnSAGl, folloWing the genetic nomenclature that is 
utiliZed for the related apicomplexan parasites T gondii and 
N. caninum [Sibley, 1991 #13; HoWe, 1999 #1759]. 
The sequence analysis for SnGAG2, SnGAG3, and 
SnGAG4 as Well as for the SnGF Cluster sequences pro 
vided by the invention and set forth herein have been derived 
in a fashion similar to that set forth above for SnGAGl. 
These novel nucleotide sequences and protein sequences of 
Sarcocyslis neurona can be utiliZed in the production of 
vaccines and/or antigen/antibody kits for prevention and 
diagnosis of Sarcocystis neurona infection. One preferred 
embodiment of the invention is a vaccine comprised of an 
alpha virus expression vector and nucleic acid selected from 
the nucleic acid sequences disclosed herein. 
Identi?cation of S. neurona Surface Antigens and 
Expression as Recombinant Proteins 
Analysis of the S. neurona EST database revealed four 
paralogous proteins that are homologous to the SAG and 
SRS surface antigens of Toxoplasma gondii. Each S. neu 
rona gene Was predicted to encode a protein that possessed 
an amino-terminal signal peptide and a carboxyl-terminal 
glycolipid anchor site, consistent With the proteins being 
surface antigens. Because of their similarity to Toxoplasma 
SAGs and their probable surface display on meroZoites, the 
four S. neurona proteins Were designated SnSAGl, 
SnSAG2, SnSAG3, and SnSAG4. The four putative surface 
antigens Were each expressed as a recombinant protein in E. 
coli, and these Were used to immuniZe rabbits and rats for 
monospeci?c polyclonal antisera production. The resulting 
polyclonal antisera Were used in Western blot analysis of 
reduced (With 2-mercaptoethanol) S. neurona lysate to 
reveal each of the SnSAGs (See, FIG. 3). The mature forms 
of native SnSAGl and SnSAG4 are predicted to be approxi 
mately 24 kDa, but these antigens co-migrated at approxi 
mately 30*32 kDa and correspond to the immunodominant 
antigen Sn30 that has been described previously (See, FIG. 
3) (Granstrom et al., 1993; Liang et al., 1998). SnSAGl has 
also been identi?ed by others as a major surface antigen 
matching the immunodominant Sn30 band (Ellison et al., 
2002), but it is apparent that SnSAG4 likely contributes to 
the antibody reactivity at this molecular Weight. The mature 
form of SnSAG2 is predicted to be about 12 kDa, but this 
antigen migrated at approximately 18*19 kDa and corre 
sponds to the previously described immunodominant Sn16 
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antigen (See, FIG. 3) (Granstrom et al., 1993; Liang et al., 
1998). Mature SnSAG3 is predicted to be 23 kDa, but 
migrated at about 28 kDa (See, FIG. 3). The aberrant 
migration of the SnSAGs under reducing conditions is a 
characteristic that has been observed previously for the 
surface antigens of both T gondii (Burg et al., 1988; 
Cesbron-DelauW et al., 1994) and N. caninum (HoWe et al., 
1998). Importantly, the Western blot experiments demon 
strated that the recombinant forms of the SnSAGs are 
recogniZed by antibodies from S. neurona-infected horses. 
There is strong concordance betWeen antibody recognition 
of recombinant SnSAGl (rSnSAGl) and standard Western 
blot analysis of complete parasite antigen (i.e., S. neurona 
meroZoite lysate). Similar results Were obtained With rSn 
SAG2, rSnSAG3, and rSnSAG4. These data demonstrate 
the utility of using the rSnSAGs in ELISA formats to 
monitor antibody responses in S. neurona-infected horses. 
EnZyme-Linked Immunosorbent Assays (ELISAs) 
Based on Recombinant S. neurona Surface 
Antigens (rSnSAGs) 
The rSnSAGs expressed in E. coli have been shoWn in 
Western blots to be recogniZed by equine antibodies; con 
sequently, these recombinant antigens can be utiliZed as the 
key reagents for developing ELISAs based on single S. 
neurona antigens. Given the teachings set forth herein and 
utiliZing methods knoWn in the art, an ELISA test can be 
developed for each of the four rSnSAGs that have been 
identi?ed by the invention, and all four assays can be 
optimiZed and evaluated in detail, as described beloW. 
Expression and Puri?cation of Recombinant SnSAGs. 
To produce highly puri?ed recombinant forms of the 
SnSAGs, the genes for each antigen have been cloned into 
the pET22b expression plasmid from Novagen (Madison, 
Wis.). This plasmid vector provides a carboxyl-terminal 
fusion to a 6-residue oligohistidine domain (His-Tag), Which 
binds to metal ion af?nity columns and alloWs for the 
ef?cient one-step puri?cation of the expressed recombinant 
protein. Plasmid constructs Were transformed into BL21 
(DE3) host cells (CodonPlus, Stratagene, Inc.), and expres 
sion of recombinant protein Was induced by addition of 
IPTG. Bacterial clones that reliably expressed the recombi 
nant SnSAGs Were selected and cyropreserved for future 
study. The recombinant S. neurona surface antigens have 
been designated rSnSAGl, rSnSAG2, rSnSAG3, and rSn 
SAG4. When recombinant protein is needed for use in the 
ELISAs, the appropriate bacterial clone can be groWn to 
logarithmic phase in LB medium, and protein expression 
can be induced by addition of IPTG to the culture. The 
recombinant protein can be extracted from inclusion bodies 
With 6 M urea and puri?ed from the host cell lysate by 
Ni++-column chromatography according to the manufactur 
er’s protocol (His-Bind resin and buffers, Novagen). To 
remove the urea, puri?ed recombinant proteins can be 
dialyZed into 350 mM NaCl, 10% glycerol, 50 mM 
NaH2PO4, 5 mM MgCl2 and stored at —20C until used. If 
necessary, recombinant proteins can be concentrated by 
centrifugal ultra?ltration in Centricon-10 columns (Ami 
con). 
Implement the rSnSAGs into ELISA Formats 
Standard antibody-capture ELISAs for microtiter plate 
format can be developed to simplify and expedite serum and 
CSF testing. For example, recombinant SnSAGl, rSnSAG2, 
rSnSAG3, or rSnSAG4 can be diluted to 1410 ug/ml in 
phosphate-buffered saline (PBS), and 100 pl of the mixture 
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can be added to each Well in high-binding capacity ELISA 
plates (Corning). After overnight incubation at 4C, Wells can 
be blocked by incubation for 1 hr With PBS containing 5% 
normal goat serum, 0.1% TWeen 20, and 0.5% non-fat dry 
milk. The primary sera or CSF samples can be diluted in PB 
S/0.1% TWeen 20 and incubated in the Wells for 2 hrs at 
room temperature. The Wells can then be Washed 4 times 
With PBS/0.1% TWeen 20 and incubated With horseradish 
peroxidase (HRP)-conjugated anti-equine immunoglobulin 
secondary antibody (Jackson Immunoresearch Labs, Inc.). 
The Wells can again be Washed With PBS/TWeen, and the 
presence of bound secondary reagent can be detected by 
addition of the chromogenic substrate O-phenylenediamine 
(Sigma-Aldrich) (HarloW and Lane, 1988). The optical 
density at 490 nm (OD490) of the reactions can be read in 
an EMax microplate reader (Molecular Devices), and results 
can be analyZed With SOFTmax PRO 4.0 computer soft 
Ware. 
The foregoing descriptions of novel and preferred 
embodiments of the invention have been presented for 
purposes of illustration and description. The descriptions are 
not intended to be exhaustive or to limit the invention to the 
precise form disclosed. Obvious modi?cations or variations 
are possible in light of the above testing. The embodiment 
Was chosen and described to provide the best illustration of 
the principles of the invention and its practical application to 
thereby enable one of ordinary skill in the art to utiliZe the 
invention in various embodiments and With various modi 
?cations as are suited to the particular use contemplated. All 
such modi?cations and variations are Within the scope of the 
invention as determined by the claims made in this appli 
cation When interpreted in accordance With the breadth to 
Which they are fairly, legally and equitably entitled. 
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